H1 Hello World

H2 Hello World

H3 Hello World

H3 Book

H4 Hello World

H4 Bold

H4 Book

Paragraph Default: Lorem ipsum dolor sit amet consectetur adipisicing elit. Fuga expedita qui illo minus fugit quaerat dolorum dolore odit incidunt, magnam quod rerum dolores sint quo distinctio magni doloribus eos adipisci.

Paragraph alt/smaller: Lorem, ipsum dolor sit amet consectetur adipisicing elit. Atque dolorum quia, eaque incidunt, magnam natus delectus vitae ipsum rerum neque sit expedita aliquam similique hic voluptatum possimus, voluptatibus ad quo?

Paragraph fine/smallest: Lorem, ipsum dolor sit amet consectetur adipisicing elit. Atque dolorum quia, eaque incidunt, magnam natus delectus vitae ipsum rerum neque sit expedita aliquam similique hic voluptatum possimus, voluptatibus ad quo?

Text Dark (Default)

Text Black

Text Teal

Text Orange

Text Purple

Text Yellow

Contact a representative VIEW DETAILS VIEW DETAILS

Lorem Ipsum VIEW DETAILS

Test Title

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Quas harum ipsum rerum aliquid quo, nam tempore optio voluptatum amet error. Ab inventore alias quos temporibus perspiciatis, nihil nemo repellendus earum?

“We are very satisfied with INOmax Total Care’s support team. They have always met our needs quickly, whether it has been the need for disposables, off-hours tech support, or additional tanks.”13

Watch this testimonial from a respiratory therapist to learn about their experience with INOmax Total Care service and support.

Watch this testimonial from a respiratory therapist to learn about their experience with INOmax Total Care service and support.

Available across our portfolio of devices

Your institution will receive our full service and support offering no matter which contract option you choose. Our contract options work for all types of NICUs. Connect with a representative to find a contract option that works best for your institution.

Contact a representative to find out more

Legacy Carousel

HRF Carousel

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION

  • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
  • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
  • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
  • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Please see Full Prescribing Information.

Reference: 1. Data on File – Ref-06557. Mallinckrodt Pharmaceuticals.

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

This website may identify third-party organizations and provide links to third-party websites or other third-party information (third-party content). The third-party content is meant for informational purposes only, is not endorsed by or under the control of Mallinckrodt, and is not meant to replace a physician’s medical advice. Mallinckrodt has no responsibility or liability for and makes no representations or warranties whatsoever about any third-party content. All trademarks, service marks, and logos appearing on this website are the property of their respective owners. Any rights not expressly granted herein are reserved.

© 2024 Mallinckrodt. All rights reserved. US-2400124 03/24

By viewing this site you agree to our Terms of Use. The product information provided in this site is intended only for residents of the United States. The product discussed herein may have different product labeling in different countries.

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION

  • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
  • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
  • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
  • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Please see Full Prescribing Information.